

**Vermont State Price Transparency Reporting**

NDC	Description	A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally;	** The estimated volume of patients who may be prescribed the drug;	Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval; and	The date and price of acquisition if the drug was not developed by the manufacturer.	The manufacturer may limit the information reported pursuant to subsection (c) of this section to that which is otherwise in the public domain or publicly available.
10019-0984-01	Cyclo 50MG USP 100 TABLETS	Oral Cyclophosphamide is a generic medication that has been on market for several years. Baxter intends to provide the product at competitive price based off the current market landscape today.	37,139	No	N/A	The information reported in this row is proprietary information demonstrating manufacturer's analysis regarding reporting.
10019-0982-01	Cyclo 25MG USP 100 TABLETS	Oral Cyclophosphamide is a generic medication that has been on market for several years. Baxter intends to provide the product at competitive price based off the current market landscape today.	5,410	No	N/A	The information reported in this row is proprietary information demonstrating manufacturer's analysis regarding reporting.

\*\*This drug is used to treat various forms of cancer. It is difficult to estimate the number of patients based on calculations. Baxter has taken the estimated number of pills per month divided by the 2020 units per IQVIA.

**General Comment:**

Cyclophosphamide Tablet is prescribed based on diagnosis and weight of the patient. While there are instances in which the monthly supply of the drug could exceed the Medicare Specialty tier of \$670.00 threshold based on the above stated factors triggering State Transparency Reporting per your State's legislation. However, Baxter Healthcare Corporation does not believe the threshold will be exceeded often.